APRESIGN 30 Tablet by Dr Precision contains 30 mg of Apremilast, a selective oral phosphodiesterase 4 (PDE4) inhibitor utilized for managing moderate to severe plaque psoriasis and psoriatic arthritis. Developed under stringent GMP standards, this oral formulation offers a non-biologic, immunomodulatory treatment alternative for adults requiring systemic therapy or phototherapy. Apremilast operates by elevating intracellular cAMP levels, resulting in the suppression of pro-inflammatory cytokines such as TNF-α, IL-17, and IL-23, while enhancing anti-inflammatory mediators, thereby effectively mitigating the inflammatory symptoms characteristic of chronic psoriatic and arthritic conditions. The medication regimen includes a carefully structured dose titration over the first six days to minimize gastrointestinal side effects and ensure optimal patient tolerance. Its safety profile supports its use in patients with mild hepatic or renal impairment without dosage adjustments. APRESIGN 30 Tablet is globally distributed by BLUEPILL EXPRESS and represents a precise, convenient oral therapy option for enhanced management of chronic inflammatory dermatologic and musculoskeletal diseases.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Apremilast 30 mg |
| Mechanism of Action | Selective phosphodiesterase 4 (PDE4) inhibition increasing intracellular cAMP |
| Therapeutic Use | Management of moderate to severe plaque psoriasis and psoriatic arthritis |
| Formulation | Oral tablet, non-biologic |
| Titration Schedule | 6-day gradual dose increase starting at 10 mg to 30 mg twice daily |
| Safety Profile | Non-immunosuppressive with favorable tolerability |
| Dose Adjustment | No adjustment needed in mild renal or hepatic impairment |
| Manufacturing Standards | GMP-compliant under Dr Precision label |
| Global Representation | Distributed by BLUEPILL EXPRESS |
| Administration | Swallow whole with or without food |
| Attributes | Description |
|---|---|
| Dosage Form | Tablet |
| Dosage Strength | 30 mg Apremilast |
| Indicated Patient Population | Adults with moderate to severe plaque psoriasis or psoriatic arthritis |
| Route of Administration | Oral |
| Packaging | 30 Tablets per pack |
| Therapeutic Class | Immunomodulator, PDE4 inhibitor |
| Storage Conditions | Store in a cool, dry place away from direct sunlight |
| Regulatory Compliance | Manufactured as per GMP standards |
| Treatment Regimen | Starts with gradual titration to 30 mg twice daily by day 6 |
| Impurities Control | Meets strict pharmaceutical testing requirements |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
Yes, APRESIGN 30 Tablet does not require dosage adjustment for patients with mild renal or hepatic impairment as per clinical guidelines.
The dosage titration starts with 10 mg on Day 1 and gradually increases over 6 days to 30 mg twice daily to reduce GI side effects risk.
It selectively inhibits PDE4 enzyme, increasing intracellular cAMP, which leads to downregulation of pro-inflammatory cytokines like TNF-α, IL-17, and IL-23 and upregulation of anti-inflammatory mediators.
No, APRESIGN 30 is a non-immunosuppressive oral therapy, offering a safer long-term treatment alternative to biologic agents.
APRESIGN 30 Tablet is globally represented and distributed by BLUEPILL EXPRESS.
Country Of Origin: India
APRESIGN 30 Tablet contains Apremilast 30 mg, an oral phosphodiesterase 4 (PDE4) inhibitor used to manage moderate to severe plaque psoriasis and psoriatic arthritis. Represented globally by BLUEPILL EXPRESS, it offers a convenient, non-biologic oral therapy for chronic inflammatory conditions.
This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.
APRESIGN 30 Tablet is a well-tolerated oral medication containing Apremilast 30 mg, primarily used in the treatment of psoriatic arthritis and moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Apremilast is a PDE4 inhibitor that works by modulating the immune response, thereby reducing inflammation and controlling disease symptoms.
The therapy offers an oral, non-immunosuppressive alternative to biologic agents, making it a convenient choice for long-term treatment with a favorable safety profile.
Apremilast inhibits the enzyme phosphodiesterase 4 (PDE4), leading to increased intracellular cAMP levels. This modulation results in a downregulation of pro-inflammatory mediators such as TNF-α, IL-17, and IL-23, and an increase in anti-inflammatory mediators, helping to control psoriatic and arthritic symptoms effectively.
Dosage and Administration:
Titration required to reduce risk of GI side effects during initiation:
Day 1: 10 mg in morning
Day 2: 10 mg morning, 10 mg evening
Day 3: 10 mg morning, 20 mg evening
Day 4: 20 mg morning, 20 mg evening
Day 5: 20 mg morning, 30 mg evening
Day 6 onward: 30 mg twice daily
Swallow whole with or without food
No dosage adjustment typically required for mild renal/hepatic impairment
Inclusive of all taxes
You Save: 0
Surat , India
Manufacturer, Contractor, Retailer, Brand Owner, Distributor, Exporter, Importer, Wholesaler, Startup
GST- 24abdfb4194j1ze
